Medicus 2013;22(2):111-114
Prof. dr. sc. Srđan Banac, dr. med.
Klinika za pedijatriju KBC-a Rijeka
51000 Rijeka, Istarska 43
e-mail:
23. 3. 2013.
March 23, 2013
18. 4. 2013.
April 18, 2013
ADRESA ZA DOPISIVANJE:
PRIMLJENO/RECEIVED:
PRIHVAĆENO/ACCEPTED:
LITERATURA
1. ERAKOVIĆHABERV. Makrolidi – više od antibiotika. Infektološki gla-
snik 2011;1:29-39.
2. GAGROA. Imunomodulacijsko djelovanje antibiotika. U: Aberle N, Bi-
tunjac M, ur. Sekundarna prevencija u pedijatriji. Osijek: Sveučilište J.
J. Strossmayera uOsijeku, 2011:90-6.
3. KANOH S, RUBIN BK. Mechanisms of action and clinical application
of macrolides as immunomodulatorymedications. ClinMicrobiol Rev
2010;23:590-615.
4. JAFFEA, FRANCISJ, ROSENTHALM, BUSHA. Long-termazithromy-
cinmay improve lung function in children with cystic fibrosis. Lancet
1998;351:420.
5. EQUI A, BALFOUR-LYNN IM, BUSH A, ROSENTHAL M. Long term
azithromycin in children with cystic fibrosis: a randomised, place-
bo-controlled crossover trial. Lancet 2002;360:978-84.
6. WOLTER J, SEENEY S, BELL S, BOWLERS, MASEL P, McCORMACK J.
Effect of long term treatment with azithromycin on diseases parame-
ters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
7. SAIMAN L, MARSHALL BC, MAYER-HAMBLETT N i sur. Azithromy-
cin inpatientswithcysticfibrosis chronically infectedwithPseudomo-
nasaeruginosa:arandomizedcontrolledtrial.JAMA2003;290:1749-56.
8. CLEMENTA, TAMALETA, LEROUXE, RAVILLY S, FAUROUXB, JAIS
JP. Long term effects of azithromycin in patients with cystic fibrosis: a
double blind, placebo controlled trial. Thorax 2006;61:895-902.
9. SAIMAN A, ANSTEAD M, MAYER-HAMBLETT N i sur. Effect of azit-
hromycin on pulmonary function in patients with cystic fibrosis unin-
fected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA 2010;303:1707-15.
10. CAI Y, CHAI D, WANG R, BAI N, LIAN BB, LIU Y. Effectiveness and
safety of macrolides in cystic fibrosis: a meta-analysis and systematic
review. J Antimicrob Chemother 2011;66:968-78.
11. ZAROGOULIDIS P, PAPANAS N, KIOUMIS I, CHATZAKI E, MALTE-
ZOS K, ZAROGOULIDIS K. Macrolides: from in-vitro anti-inflamma-
tory and immunomodulatory properties to clinical practice in respira-
tory diseases. Eur J Clin Pharmacol 2012;68:479-503.
12. KABRA SK, PAWAIYAR, LODHAR i sur. Long-termdaily high and low
doses of azithromycin in children with cystic fibrosis: a randomized
controlled trial. J Cyst Fibros 2010;9:17-23.
13. CYMBALA AA, EDMONDS LC, BAUER MA i sur. The disease modi-
fying effects of twice-weekly oral azithromycin in patients with bron-
chiectasis. Treat RespirMed 2005;4:117-22.
14. RICHELDI L, FERRARA G, FABBRI L, LASSERSON J, GIBSON PG.
Macrolides for chronic asthma. Cochrane Database Syst Rev 2005:
CD002997.
15. EKICI A, EKICI M, ERDEMOGLUAK. Effect of azithromycin on the se-
verity of bronchial hyperresponsiveness in patients withmild asthma.
J Asthma 2002;39:181-5.
16. PIACENTINI GL, PERONI DG, BODINI A i sur. Azithromycin reduces
bronchial hyperresponsiveness and neutrophilic airway inflammati-
on in asthmatic children: a preliminary report. Allergy Asthma Proc
2007;28:194-8.
17. STRUNKRC,BACHARIERLB,PHILIPSBRisur.Azithromycinormon-
telukast as inhaled corticosteroid-sparing agents inmoderate-to-seve-
re childhood asthma study. J Allergy Clin Immunol 2008;122:1138-44.
18. SHINKAI M, HENKE MO, RUBIN KB. Macrolide antibiotics as immu-
nomodulatorymedications: proposedmechanismsofaction. Pharma-
col Ther 2008;117:393-405.
19. BLASI F, MANTEROM, ALIBERTI S. Antibiotics as immunomodulant
agents in COPD. Curr Opin Pharmacol 2012;12:293-9.
20.HODGE S, HODGE G, JERSMANN H i sur. Azithromycin improves
macrophage phagocytic function and expression of mannose receptor
in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2008;178:139-48.
21. ALBERT RK, CONNETT J, BAILEYWC i sur. Azithromycin for preven-
tion of exacerbations of COPD. NEngl JMed 2011;365:689-98.
22.CERVIN A, KALM O, SANDKULL P, LINDBERG S. One-year low-dose
erythromycin treatment of persistent chronic sinusitis after sinus sur-
gery: clinical outcome and effects on mucociliary parameters and na-
sal nitric oxide. Otolaryngol HeadNeck Surg 2002;126:481-9.
23.SHINKAI M, RUBIN BK. Macrolides and airway inflammation in chil-
dren. Paediatr Respir Rev 2005;6:227-35.
114
Banac S.
